论文部分内容阅读
随着新药的不断问世,出现了新的配伍禁忌问题,而有些新药的配伍禁忌未列入《静脉药物配伍禁忌表》中,如左氧氟沙星氯化钠注射液静脉输注后,接输头孢哌酮钠他唑巴坦钠1.0g放入生理盐水100mL中时,茂菲氏滴管内即出现白色絮状物。调换输入药物的顺序,仍出现上述现象,说明存在配伍禁忌。1用法左氧氟沙星氯化钠注射液0.5g静脉输注,头孢哌酮钠他唑巴坦钠1.0g溶于100mL生理盐水中静脉输注,每天1次。将左氧氟沙星氯化钠注射液0.5g按照输液操作常规静脉输入,输注速度为40gtt/min～60gtt/min,输液通畅,输液管内液体澄清,无异常反应。静脉输注完后为病人换上配有头孢哌酮
With the advent of new drugs, there has been a new compatibility taboo problem, and some new drug compatibility taboo has not been included in the “intravenous drug compatibility taboo table”, such as levofloxacin sodium chloride injection after intravenous infusion of sodium cefoperazone sodium When 1.0 Bactam sodium is placed in 100 mL of normal saline, white floccules appear in the tube of Mauve’s eosinophil. Exchange the order of imported drugs, there is still the above phenomenon, indicating the existence of compatibility taboo. 1 usage Levofloxacin sodium chloride injection 0.5g intravenous infusion, cefoperazone sodium tazobactam sodium 1.0g dissolved in 100mL saline intravenously once a day. The levofloxacin sodium chloride injection 0.5g intravenous infusion operation routine intravenous infusion rate of 40gtt / min ~ 60gtt / min, infusion patency, liquid infusion tube clear, no abnormal reaction. After the intravenous infusion for patients with cefoperazone